BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 12134366)

  • 1. Positron emission tomography imaging in melanoma and lymphoma.
    Abella-Columna E; Valk PE
    Semin Roentgenol; 2002 Apr; 37(2):129-39. PubMed ID: 12134366
    [No Abstract]   [Full Text] [Related]  

  • 2. Positron emission tomography (PET) in the evaluation of patients with cancer.
    Godwin HA; Zuger JH
    Trans Am Clin Climatol Assoc; 1999; 110():181-94. PubMed ID: 10344016
    [No Abstract]   [Full Text] [Related]  

  • 3. [Positron emission tomography (PET) in clinical oncology. Part II].
    Cabrera Villegas A; Gámez Cenzano C; Martín Urreta JC
    Rev Esp Med Nucl; 2002 Apr; 21(2):131-47; quiz 149-51. PubMed ID: 11879626
    [No Abstract]   [Full Text] [Related]  

  • 4. PET/CT in oncology: integration into clinical management of lymphoma, melanoma, and gastrointestinal malignancies.
    Schöder H; Larson SM; Yeung HW
    J Nucl Med; 2004 Jan; 45 Suppl 1():72S-81S. PubMed ID: 14736838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients.
    Mijnhout GS; Pijpers R; Hoekstra OS; Teule GJ; Borgstein PJ; Meijer S
    Cancer; 1999 Mar; 85(5):1199-201. PubMed ID: 10091807
    [No Abstract]   [Full Text] [Related]  

  • 6. Oncological applications of FDG PET imaging: brain tumors, colorectal cancer, lymphoma and melanoma.
    Delbeke D
    J Nucl Med; 1999 Apr; 40(4):591-603. PubMed ID: 10210218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluorodeoxyglucose positron emission tomography in the presence of cardiac metastases.
    Nguyen JD; Carrasquillo JA; Little RF; Ryan QC; Wilson W; Chen CC
    Clin Nucl Med; 2003 Dec; 28(12):979-80. PubMed ID: 14663321
    [No Abstract]   [Full Text] [Related]  

  • 8. Use of [F]-fluorodeoxyglucose positron emission tomography in monitoring response of recurrent neurotropic desmoplastic melanoma to radiotherapy.
    Hannah A; Feigen M; Quong G; Akhurst T; Berlangieri SU; Zimet A; Zalcberg J; McKay WJ; Scott AM
    Otolaryngol Head Neck Surg; 2000 Feb; 122(2):304-6. PubMed ID: 10652412
    [No Abstract]   [Full Text] [Related]  

  • 9. [Diagnosis of colorectal cancer with FDG-PET].
    Uno K
    Nihon Rinsho; 2003 Sep; 61 Suppl 7():168-72. PubMed ID: 14574875
    [No Abstract]   [Full Text] [Related]  

  • 10. Positron emission tomography and colorectal carcinoma: an update.
    Tzimas GN; Koumanis DJ; Meterissian S
    J Am Coll Surg; 2004 Apr; 198(4):645-52. PubMed ID: 15051018
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical applications of FDG-PET in oncology.
    Czernin J
    Acta Med Austriaca; 2002; 29(5):162-70. PubMed ID: 12506767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Normal and abnormal patterns of 18F-fluorodeoxyglucose PET/CT in lymphoma.
    Bar-Shalom R
    Radiol Clin North Am; 2007 Jul; 45(4):677-88, vi-vii. PubMed ID: 17706532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of breast and gynecologic cancers by positron emission tomography.
    Dehdashti F; Siegel BA
    Semin Roentgenol; 2002 Apr; 37(2):151-68. PubMed ID: 12134368
    [No Abstract]   [Full Text] [Related]  

  • 14. A new imaging technique for colorectal cancer: positron emission tomography.
    Flamen P; Van Cutsem E; Mortelmans L
    Semin Oncol; 2000 Oct; 27(5 Suppl 10):22-9. PubMed ID: 11049029
    [No Abstract]   [Full Text] [Related]  

  • 15. Positron emission tomography/computed tomography in melanoma.
    Bourgeois AC; Chang TT; Fish LM; Bradley YC
    Radiol Clin North Am; 2013 Sep; 51(5):865-79. PubMed ID: 24010910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluorodeoxyglucose positron emission tomography for melanoma staging: refining the indications.
    Wagner JD
    Ann Surg Oncol; 2006 Apr; 13(4):444-6. PubMed ID: 16491336
    [No Abstract]   [Full Text] [Related]  

  • 17. Malignant melanoma staging using whole-body positron emission tomography.
    Paquet P; Hustinx R; Rigo P; Piérard GE
    Melanoma Res; 1998 Feb; 8(1):59-62. PubMed ID: 9508378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The utility of 2-deoxy-2-[18F]fluoro-D-glucose-positron emission tomography and combined positron emission tomography and computed tomography in lymphoma and melanoma.
    Macapinlac HA
    Mol Imaging Biol; 2004; 6(4):200-7. PubMed ID: 15262235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical role of positron emission tomography in oncology.
    Bomanji JB; Costa DC; Ell PJ
    Lancet Oncol; 2001 Mar; 2(3):157-64. PubMed ID: 11902566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of unsuspected metastasis in a melanoma patient with positron emission tomography.
    Argenyi EE; Dogan AS; Urdaneta LF; Ponto LL; Hichwa RD; Watkins GL
    Clin Nucl Med; 1995 Aug; 20(8):744-7. PubMed ID: 7586890
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.